Capricor Therapeutics Inc — Quarterly Cash Flow (NASDAQ:CAPR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 92.95 M170.48 M153.77 M133.57 M126.44 M Total liabilities 24.69 M25.02 M26.12 M28.59 M42.57 M Total equity 68.26 M145.46 M127.65 M104.98 M83.87 M Total liabilities & shareholders' equities 92.95 M170.48 M153.77 M133.57 M126.44 M Total debt ————— Net debt —————

News

Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor to submit HOPE-3 data to FDA for DMD therapy review

Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterates Overweight rating on Capricor stock

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Piper Sandler reiterates Capricor stock rating, names it 2026 top pick

PPMD to host webinar on Capricor’s DMD therapy trial results

Piper Sandler raises Capricor Therapeutics stock price target to $45 on trial success

Oppenheimer raises Capricor Therapeutics price target to $54 on positive trial data